Age should not affect chemotherapy choice for stage IV lung cancer: guidelines
Early PET-CT predicts treatment response of head and neck cancer
Evidence scarce to support RF ablation of colorectal CA metastases in the liver
Casopitant helps curb chemotherapy emesis
Australian scientists plan to regrow breasts after cancer
NEW YORK (Reuters Health) - A moderate delay in starting radiotherapy after surgery for glioblastoma multiforme appears not to be harmful, and may even be helpful, according to Israeli and North American researchers.
Indeed, lead investigator Dr. Deborah T. Blumenthal told Reuters Health, "We were surprised to find that there was a statistically significant improved survival associated with delay of initiation of therapy, comparing early onset of radiation -- 2 weeks after surgery -- to 6 weeks."
Dr. Blumenthal of Tel Aviv Sourasky Medical Center and colleagues analyzed data on more than 2800 patients with glioblastoma treated in Radiation Therapy Oncology Group clinical trials from 1973 to 2003.
Delays in starting radiotherapy fell into four categories: less than 2 weeks, 2-3 weeks, 3-4 weeks, and 4-6 weeks.
According to their report in the December 29th on-line issue of the Journal of Clinical Oncology, there was no reduced survival with increasing delay. Moreover, median actuarial survival in the group with the longest delay was 12.5 months, compared with 9.2 months in patients with a less-than-2-week delay.
"Delaying the initiation of standard radiation treatment for glioblastoma up to 6 weeks," Dr. Blumenthal concluded, "does not have detrimental effect on outcome, and in fact, appears to be associated with improved survival."
Copyright © 2009 Reuters Limited. All rights reserved. Republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world.